Related to AVEO Earns $5M Milestone from Biogen Idec as Part of ErbB3 Antibody Collaboration

• Biogen Idec Restructuring Will Close Sites & Divest Cancer Assets to Save $300M a Year
  
• Protagen to Help Biogen Idec Find Biomarkers for Multiple Sclerosis Therapy
  
• Australia Approves Biogen Idec’s Fampyra for Improving Walking Ability in Multiple Sclerosis
  
• Adimab Signs Separate Antibody Discovery Deals with Biogen Idec and Novo Nordisk
  
• Biogen Idec and Portola Forge $45M Pact to Tackle Autoimmune and Inflammatory Diseases
  
• Aveo Signs BI on as Production Partner for Clinical-Stage mAb
  
• Biogen Idec, Samsung Establish $300M Biosimilar Joint Venture
  
• Phase III Results Lead Aveo and Astellas to Plan Regulatory Submissions for Tivozanib
  
• Biogen Idec Pays Isis $29M for Option to Early-Clinical SMA Antisense Therapy
  
• FDA Approves Tysabri Label Change and Test for JC Virus Infection in MS Patients
  
• Biogen Idec Takes Option to MAKScientific MS Program
  
• Aveo, Astellas Report Positive Data from Phase III Comparative Tivozanib Trial in RCC
  
• New Data Released for Tivozanib Against RCC
  
• Biogen Idec Pays Isis $3.5M for Antisense Drug Milestone
  
• OSI to Pay $20M to Broaden Cancer Partnership with AVEO
  
• GSK and Enigma to Develop Point-of-Care Flu Diagnostic
  
• Merck & Co. Returns Rights to Mid-Stage Anticancer Agent to AVEO
  
• OSI Pays Aveo $25M for Rights to Use Human Response Platform
  
• Astellas Gains Ex-Asia Rights to Aveo's Phase III Cancer Drug
  
• Biogen Idec Signs Up to Help Aveo Develop Its Discovery-Stage Cancer Program